Long-term immune responses to SARS-CoV-2 Omicron BA.4/5 mRNA booster in people living with HIV.

ABSTRACT:

Background

Variant-adapted vaccines are recommended in vulnerable populations to address the waning immunity and the emergence of immune-escaping SARS-CoV-2 variants, yet data about immune responses to such vaccines in people living with HIV (PLWH) are limited. We therefore aimed to assess long-term immune responses to an original-BA.4/5 mRNA booster in this population.

Methods

In this prospective longitudinal study, PLWH receiving either an original-BA.4/5 bivalent booster or an original monovalent booster and HIV-negative healthcare workers (HCWs) receiving a bivalent booster were enrolled and sampled before (T0), 1 month (T1), and 4-9 months (T2) after the vaccine administration. SARS-CoV-2-specific T and B cells, RBD-binding antibodies, and RBD-blocking antibodies agains

SUBMITTER: Augello M 

PROVIDER: S-EPMC11950219 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature